Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 18 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
Q2 2024 vs. Q1 2024
How the institutions holding Pharvaris N.V. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 35 | 36 | +1 |
| Shares | 42.4M | 43.0M | +583.0K (+1.4%) |
| Value | $980.5M | $808.6M | −$171.9M (−17.5%) |
New holders (5)
Institutions that held Pharvaris N.V. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HealthInvest Partners AB | 34,328 | $645.4K | 0.39% |
| Y-Intercept (Hong Kong) Ltd | 15,883 | $298.6K | 0.02% |
| Virtus ETF Advisers LLC | 5,001 | $94.0K | 0.05% |
| Wells Fargo & Company | 700 | $13.2K | 0.00% |
| UBS Group AG | 167 | $3.14K | 0.00% |
Sold out (4)
Institutions that held Pharvaris N.V. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Qube Research & Technologies Ltd | 30,138 | $696.5K |
| Hudson Bay Capital Management LP | 20,018 | $462.6K |
| Jump Financial, LLC | 11,700 | $270.4K |
| JPMorgan Chase & Co | 3,150 | $72.8K |